期刊文献+

托拉塞米片人体生物等效性研究 被引量:3

Bioequivalence Study of Torasemide Tablets in Healthy Chinese Volunteers
原文传递
导出
摘要 目的用高效液相色谱-质谱法测定健康男性受试者单次空腹口服受试及参比托拉塞米片后的血药浓度,计算受试制剂和参比制剂的药动学参数,评价两种制剂是否生物等效。方法采取两制剂、双周期、交叉的设计试验,24例男性健康受试者单剂量口服受试制剂和参比制剂的托拉塞米片,以HPLC-MS测定血浆中的托拉塞米浓度。采用SPSS及BAPP2.2软件处理计算主要药动学参数。结果受试制剂与参比制剂中托拉塞米的ρ_(max)分别为(1 408.29±337.27)和(1 487.86±360.24)ng·mL^(-1),t_(max)分别为(0.90±0.42)和(1.03±0.50)h,t_(1/2)分别为(4.43±0.57)和(4.43±0.60)h,MRT分别为(3.90±0.60)和(4.01±0.72)h,AUC_(0-24 h)分别为(3 886.86±865.99)和(3 906.06±761.72)ng·h·mL^(-1),AUC_(0-∞)分别为(3 936.57±903.93)和(3 956.96±789.98)ng·h·mL^(-1)。按AUC_(0-24 h)和AUC_(0-∞)计算,受试制剂的相对生物利用度分别为(99.8±11.7)%和(99.7±12.0)%。结论两种制剂在健康人体内具有生物等效性。 OBJECTIVE To evaluate the bioequivalence of tested and reference torasemide tablets in healthy male volunteers.METHODS A single oral dose of the two formulations was given to 24 healthy male volunteers according to a randomized crossover design. Plasma drug concentrations were determined by HPLC-MS. RESULTS The pharmacokinetic parameters of torasemide of the two preparations were as follows: ρ(max)( 1 408. 29 ± 337. 27) and( 1 487. 86 ± 360. 24) ng·mL-1,t(max)( 0. 90 ± 0. 42) and( 1. 03 ±0. 50) h,t(1/2)( 4. 43 ± 0. 57) and( 4. 43 ± 0. 60) h,MRT( 3. 90 ± 0. 60) and( 4. 01 ± 0. 72) h,AUC(0-24 h)( 3 886. 86 ± 865. 99) and( 3 906. 06 ± 761. 72) ng·h·mL-1,AUC(0-∞)( 3 936. 57 ± 903. 93) and( 3 956. 96 ± 789. 98) ng·h·mL-1,respectively. The relative bioavailability of tested torasemide tablets were( 99. 8 ± 11. 7) % and( 99. 7 ± 12. 0) % when calculated by AUC(0-24 h) and AUC(0-∞),respectively. CONCLUSION The two formulations of torasemide are bioequivalent in healthy Chinese volunteers.
作者 周晓雯 姚毅
出处 《中国药学杂志》 CAS CSCD 北大核心 2017年第16期1442-1446,共5页 Chinese Pharmaceutical Journal
关键词 托拉塞米 生物等效性 高效液相色谱-质谱 torasemide bioequivalence HPLC-MS
  • 相关文献

参考文献5

二级参考文献32

  • 1刘惠侠.长效袢利尿药托拉塞米临床研究进展[J].世界临床药物,2004,25(8):495-498. 被引量:11
  • 2蒋文,李一石,黄一玲,田蕾,黄岩,刘晗,苏绮,王蓓,成小如,姚康宝,华潞,张阴凤.托拉塞米片的正常人体药动学研究[J].中国新药杂志,2004,13(9):828-831. 被引量:7
  • 3况扶华,华潞,田蕾,黄一玲,黄岩,刘晗,苏绮,王蓓,成小如,张阴凤,李一石.托拉塞米片多次给药药动学研究[J].中国药学杂志,2005,40(9):693-695. 被引量:7
  • 4[1]Greger R.Inhibition of active NaCl reabsorption in the thick ascending limb of the loop of Henle by torasemide[J].Arzneimittelforsch,1988,38(1A):151-152.
  • 5[2]Cuvelier R,Pellegrin P,Lesen M,et al.Site of action of torasemide in man[J].Eur J Clin Phamacol,1986,31(Suppl):S15-S19.
  • 6[3]Brater DC.Clinical pharmacology of loop diuretics[J].Drugs,1991,41(Supp 3):S14-S22.
  • 7[4]Knauf H,Mutschler E.Clinical pharmacokinetics and pharmacodynamics of torasemide[J].Clin Pharmacokinet,1998,34(1):1-24.
  • 8[5]Lesne M.Comparison of the pharmacokinetics and pharmacodynamics of torasemide and furosemide in healthy volunteers[J].Arzneimittelforsch,1988,38(1A):160-163.
  • 9[6]Friedel HA,Buckley MMT.Torasemide-a review of its pharmacology,properties and therapeutic potential[J].Drugs,1991,41(1):81-103.
  • 10[7]Neugebauer G,Besenfelder E,Von Moellendorff E.Pharmacokinetics and metabolism of torasemide in man[J].Arzneimittelforsch,1988,38(1):164-166.

共引文献20

同被引文献68

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部